Abstract:BACKGROUND Most international guidelines currently recommend methylxanthines (e.g., theophylline, aminophylline) for severe exacerbations of chronic obstructive pulmonary disease (COPD), yet clinical trials underlying this recommendation have been small and underpowered. OBJECTIVES To determine the benefit of methylxanthines compared to placebo for COPD exacerbations. SEARCH STRATEGY Randomised controlled trials (RCTs) were identified from the Cochrane Airways Review Group COPD Register, a compilation of systematic searches of CINAHL, EMBASE, MEDLINE and CENTRAL and hand searching of 20 respiratory journals. Primary authors and content experts were contacted to identify eligible studies. Bibliographies from included studies and reviews were searched. SELECTION CRITERIA Included studies were limited to RCTs of patients presenting with acute COPD exacerbations, treated with methylxanthines (oral or intravenous) or placebo plus standard care. Two reviewers independently selected articles for inclusion and assessed methodological quality. DATA COLLECTION AND ANALYSIS Two reviewers independently extracted data. Missing data were obtained from authors or calculated from other data presented in the paper. The data were analysed using the Cochrane Review Manager 4.1. Studies were pooled to yield weighted mean differences (WMD), standardised mean difference (SMD) or odds ratios (OR) and reported using 95% confidence intervals (95%CI). MAIN RESULTS From 29 identified references, 4 RCTs met inclusion criteria (169 patients). Mean change in forced expiratory volume in one second (FEV1) at 2 hours was similar in methylxanthine and placebo groups. Data on clinical outcomes were sparse. Trends toward improvements in hospitalisation and length-of-stay were offset by a trend toward more relapses at one week. Changes in symptom scores were not significant. Methylxanthines caused more nausea and vomiting than placebo (OR: 4.6; 95% CI: 1.7 to 12.6) and trended toward more frequent tremor, palpitations, and arrhythmias. REVIEWER'S CONCLUSIONS Given current evidence, methylxanthines should not be used for COPD exacerbations. Possible beneficial effects in lung function and clinical endpoints were modest and inconsistent, whereas adverse effects were significantly increased. More selective agents, tested in larger randomised trials, are necessary if methylxanthines are to have any role in the treatment of COPD exacerbations.

Methocinnamox is a Potent and Long-Acting Antagonist that can Prevent and Reverse Opioid-Induced Respiratory Depression

Comparison of the μ -opioid receptor antagonists methocinnamox (MCAM) and naloxone to reverse and prevent the ventilatory depressant effects of fentanyl, carfentanil, 3-methylfentanyl, and heroin in male rats

Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement

Time Course of Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review

Countermeasures for Preventing and Treating Opioid Overdose

Intravenous ghrelin accelerates postoperative gastric emptying and time to first bowel movement in humans

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) As a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment

Mechanistic pharmacokinetic-pharmacodynamic modeling and simulations of naloxone auto-injector 10 mg reversal of opioid-induced respiratory depression

Isolation of plasma membranes and Golgi apparatus from a single chicken liver homogenate

Potency, dissociation kinetics and reversibility of fentanyls and nitazenes by naloxone at the μ opioid receptor

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Countering Opioid-induced Respiratory Depression in Male Rats with Nicotinic Acetylcholine Receptor Partial Agonists Varenicline and ABT 594.

A µ-opioid receptor modulator that works cooperatively with naloxone

Ampakine CX717 Protects Against Fentanyl-induced Respiratory Depression and Lethal Apnea in Rats

Are carfentanil and acrylfentanyl naloxone resistant?

Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose

Methylxanthines for exacerbations of chronic obstructive pulmonary disease.

Preclinical Characterization and Development on NAQ As a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment